Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA

[cafead]

via Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination therapy, Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor).

article source